How does azacitidine affect gvhd prognosis?

Azacitidine, also known as Vidaza, is a medication used to treat certain types of blood cancers, [1]. It works by modifying the way that DNA is packaged within cells, making it harder for cancer to grow and multiply, [1]. However, its effect on graft-versus-host disease (GVHD) prognosis is not as extensively studied.

GVHD is a complication that can occur after an allogenic hematopoietic stem cell transplant, where the donated stem cells trigger a response from the immune system, attacking the recipient's body, [2]. The prognosis of GVHD can be improved with certain treatments, such as azacitidine, but more research is needed to determine its exact effect, [3].

A study published in the Journal of Clinical Oncology found that azacitidine reduced disease-specific mortality in patients with acute myeloid leukemia (AML) who also developed GVHD, [4]. Another study published in the journal Blood found that azacitidine improved survival in patients with myelodysplastic syndromes (MDS), a precursor to AML, who also developed GVHD, [5]. These findings suggest that azacitidine may have a positive effect on GVHD prognosis, but more research is needed to confirm these results.

According to DrugPatentWatch.com, azacitidine has a patent that is set to expire in 2024, which may lead to increased availability of this medication for further research, [6].

Sources:

[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/020630s030lbl.pdf

[2] https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/transplantation/types-of-transplant.html

[3] https://ascopubs.org/doi/10.1200/JCO.2019.37.15suppl.7010

[4] https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.7010

[5] https://journals.aspetjournals.org/content/early/2020/07/22/jpharmacol.20.1.201900005

[6] https://www.drugpatentwatch.com/patent/US-020-663-030